Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (EP1270554) Sulfonyl urea derivatives and their use in the control of interleukin-1 activity

Office : European Patent Office
Application Number: 02020750 Application Date: 29.12.1997
Publication Number: 1270554 Publication Date: 02.01.2003
Publication Kind : A1
Designated States: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
IPC:
A 61K
C 07C
A61K 31/00
C07C 311/60
C07C 317/14
C07C 323/67
C07D 209/08
C07D 307/64
C07D 317/18
C07D 333/34
C07D 335/06
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
64
Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
311
Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
50
Compounds containing any of the groups X being a hetero atom, Y being any atom
52
Y being a hetero atom
54
either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
311
Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
50
Compounds containing any of the groups X being a hetero atom, Y being any atom
52
Y being a hetero atom
54
either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
57
having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
60
having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
317
Sulfones; Sulfoxides
14
having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
323
Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
64
containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
67
containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
209
Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
02
condensed with one carbocyclic ring
04
Indoles; Hydrogenated indoles
08
with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
307
Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
02
not condensed with other rings
34
having two or three double bonds between ring members or between ring members and non-ring members
56
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
64
Sulfur atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
317
Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
08
having the hetero atoms in positions 1 and 3
10
not condensed with other rings
14
with substituted hydrocarbon radicals attached to ring carbon atoms
18
Radicals substituted by singly bound oxygen or sulfur atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
333
Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
02
not condensed with other rings
04
not substituted on the ring sulfur atom
26
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
30
Hetero atoms other than halogen
34
Sulfur atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
335
Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
04
condensed with carbocyclic rings or ring systems
06
Benzothiopyrans; Hydrogenated benzothiopyrans
CPC:
C07D 335/06
C07C 311/60
C07C 317/14
C07C 323/67
C07C 2601/02
C07C 2601/04
C07C 2601/08
C07C 2601/14
C07C 2602/10
C07D 209/08
C07D 307/64
C07D 317/18
C07D 333/34
Applicants: PFIZER
Inventors: DOMBROSKI MARK ANTONY
EGGLER JAMES FREDRICK
Priority Data: 97947201 29.12.1997 EP
3697997 29.01.1997 US
Title: (DE) Sulfonylharnstoff-Derivate und deren Verwendung in der Steuerung der Interleukin-1-Wirkung
(EN) Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
(FR) Dérivés de sulfonylurée et leur emploi dans le contrôle de l'activité de l'interleukine-1
Abstract:
(EN) The invention relates to a compound of the formula wherein R<1> and R<2> are as defined in the description, useful in the treatment and condition selected from the group consisting of meningitis and salpingitis, septic shock, disseminated intravascular coagulation, and/or adult respiratory distress syndrome, acute or chronic inflammation, arthritis, cholangitis, colitis, encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury, vasculitis, acute and delayed hypersensitivity, graft rejection, and graft-versus-host disease, auto-immune diseases including Type 1 diabetes mellitus and multiple sclerosis, periodonate diseases, interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, keloid formation, tumors which produce IL-1 as an autocrine growth factor, cachexia, Alzheimers disease, percussion injury, depression, atherosclerosis (including cardiomyopathy, myocarditis and heart failure) and osteoporosis in a mammal, including a human.
Also published as:
CZPV1999-2575IS5099NO19993658SK98299TR1999/01816YUP-337/99
MXPA/a/1999/007030KR1020000070541SG65991VN4111IL130855MA26468
AR011093EP0964849EP1270565US6166064JP2000511200 CN1245490
CA2279186EA199900603DE000069722663DE000069729762PT964849PT1270565
NZ336248AU1998052340VN4111MYPI 98000291BG103597WO/1998/032733